InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This digital ...

Phased flight relocation begins at King Khalid International under Terminal Transition Planes prepare for take off at King Khalid Airport in Riyadh. Illustrative image. Dubai: King Khalid ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:10 PM ESTCompany ParticipantsMichael Morrissey - CEO, President ...

Human MAP1LC3B (LC3B) binds proteins involved in autophagy and other cellular processes using a degenerate four-residue short linear motif known as the LC3-interacting region (LIR). Biochemical and ...

CNA speaks to local leaders and businesses in Indonesia’s Batam on how Nongsa Digital Park is anchoring the city’s push to become a regional digital economy hub, even as challenges around talent and ...